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What potential research participants
want to know about research:
a systematic review
Helen Michelle Kirkby,1 2Melanie Calvert,1 Heather Draper,2 Thomas Keeley,1
Sue Wilson1
ABSTRACT
Objective: To establish the empirical evidence base
for the information that participants want to know
about medical research and to assess how this relates
to current guidance from the National Research Ethics
Service (NRES).
Data sources: Medline, Web of Science, Applied
Social Sciences Index and Abstracts, Sociological
abstracts, Health Management Information
Consortium, Cochrane Library, thesis index’s, grey
literature databases, reference and cited article lists,
key journals, Google Scholar and correspondence with
expert authors.
Study selection: Original research studies published
between 1950 and October 2010 that asked potential
participants to indicate how much or what types of
information they wanted to be told about a research
study or asked them to rate the importance of
a specific piece of information were included.
Study appraisal and synthesis methods: Studies
were appraised based on the generalisability of results
to the UK potential research participant population. A
metadata analysis using basic thematic analysis was
used to split results from papers into themes based on
the sections of information that NRES recommends
should be included in a participant information sheet.
Results: 14 studies were included. Of the 20 pieces of
information that NRES recommend should be included
in patient information sheets for research pooled
proportions could be calculated for seven themes.
Results showed that potential participants wanted to
be offered information about result dissemination
(91% (95% CI 85% to 95%)), investigator conflicts of
interest (48% (95% CI 27% to 69%)), the purpose of
the study (76% (95% CI 27% to 100%)), voluntariness
(39% (95% CI 2% to 100%)), how long the research
would last (61% (95% CI 16% to 97%)), potential
benefits (57% (95% CI 7% to 98%)) and
confidentiality (44% (95% CI 10% to 82%)). The level
of detail participants wanted to know was not explored
comprehensively in the studies. There was no
empirical evidence to support the level of information
provision required by participants on the remaining
seven items.
Conclusions: There is limited empirical evidence on
what potential participants want to know about
research. The existing empirical evidence suggests
that individuals may have very different needs and
a more tailored evidence-based approach may be
necessary.
INTRODUCTION
Medical research is central to the advance-
ment of treatments, services and tech-
nology.1e3 Potential participants have the
right to choose whether they participate in
medical research,4 5 and individuals must
give their consent prior to participating in
research. As part of this ongoing process,
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ARTICLE SUMMARY
Article focus
- What information do potential participants want
to know when they are deciding whether to take
part in research?
- What is the established empirical evidence base?
- How does the current empirical evidence base
relate to current guidance from the NRES?
Key messages
- There is little empirical evidence of what
information potential participants want to know
about research when they are making the
decision to take part.
- The limited empirical evidence available suggests
that potential participants may have very different
information needs.
- Further research is required to determine what
potential participants really want to know about
research and how this can be delivered in a way
that takes into account their different informa-
tional needs.
Strengths and limitations of this study
- An extensive search strategy ensured that the
review was systematic in capturing all available
empirical evidence.
- Papers included in the review differed in their
methodologies and presentation of results,
making comparisons between papers extremely
difficult.
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potential participants must be provided with sufficient
information to make a voluntary and informed deci-
sion.2 6e11 In research settings, study information is
usually conveyed to potential participants in the form of
a written participant information sheet (PIS), which is
later reinforced by a verbal consent interview with
a member of the research team.12
In the UK, the National Research Ethics Service
(NRES) provides extensive guidance on how a PIS
should be written and presented. The guidance suggests
that a PIS should be split into two parts where part one
provides a brief and clear explanation of the essential
elements of the specific study and allows participants to
make an initial choice of whether the study is of interest.
Part two should then contain additional information
on matters such as confidentiality, indemnity and
publication intentions.
There is some concern that PIS have become
increasingly lengthy over recent years.10 13 14 Complex
studies, for example, where the potential participant
might, for example, on the basis of test results be invited
to participate in a further phase of the study, often use
detailed and lengthy PISs. This can lead to poor
understanding by participants15e17 and a corresponding
concern that consent criteria are not always met. The
NRES guidance is not explicit in the level of detail to be
included in a PIS, and there is disagreement among
experts about how much information to include.18 If
PISs become so complex that only the most confident
and educated participants are able to digest all the
information, this may result in selection bias meaning
that research is less generalisable.19 Furthermore, there
is a risk that healthcare researchers are becoming
increasingly paternalistic in their information provision
without recognising individual participant needs. In
order to help address the problem of how much infor-
mation to include in PIS, we conducted a systematic
review that aimed to establish the empirical evidence
base for the information that potential participants want
to know when they are deciding about participation.
METHODS
Selection criteria and literature search
This systematic review included all studies that asked
participants to indicate how much or what type of
information they wanted to be told about a research
study or asked them to rate the importance of a specific
piece of information. We included studies published
between 1950 and 27 October 2010 with no limit to
language or participant group. We only included studies
of participant opinion and excluded studies of health-
care professional or other expert opinion.
We combined Mesh terms Patient, Research Subjects,
Consent forms, Informed Consent and Research ethics
with terms relating to information provision (online
appendix 1). We conducted searches in Medline, Web of
Science, Applied Social Sciences Index and Abstracts,
Sociological abstracts, Health Management Information
Consortium and the Cochrane Library electronic data-
bases. We also searched thesis index’s, grey Literature
databases, reference and cited article lists, key journals
and Google Scholar and we asked expert authors to
identify relevant studies.
We did not conduct a formal quality assessment of
included literature because there were both quantitative
and qualitative studies, widely varied study methods and
different types of results that were often not comparable
between papers. Instead, we conducted a critical
appraisal of each paper using five quality indicators
(response rate, sample size, demographics, participant
characteristics and strengths and limitations of study
methods). The strengths and limitations of each study
are presented in table 1.
Data extraction and synthesis
One researcher (HMK) extracted data from papers
using a pre-defined data extraction sheet and a second
researcher (TK) checked it for accuracy with disagree-
ments resolved by discussion between these two authors
(table 1). A metadata analysis using basic thematic
analysis was used to analyse the data from the 14 papers.
Themes were based on the sections of information that
NRES recommends should be included in a PIS
(table 2).10 Each paper was assessed to identify any
further themes relating to what information research
participants may want to know. A metadata analysis
coded individual results based on their relevance to each
theme and then themes were collated to report overall
results. For themes where more than one quantitative
study reported a proportion of participants wanting to
know the information, pooled proportions with random
effects were calculated using StatsDirect statistical
software (StatsDirect Ltd).
RESULTS
The search yielded 11 943 unique references. We
discarded 11 291 after reviewing the title, 620 after
reviewing the abstract and a further 18 after reviewing
the full paper (figure 1). HMK conducted the citation
screening and TK independently validated approxi-
mately 10% of the references identified from electronic
databases (96.0% k agreement rate). All 14 included
studies were identified from searches of Medline and
Applied Social Sciences Index and Abstracts. Expert
authors identified 37 unique references; 13 were dupli-
cates from the electronic searches and 24 did not meet
the inclusion criteria.
Of the 14 studies included in the review, three specif-
ically considered the return of research results to
participants and six considered only investigator
conflicts of interest. Five studies looked broadly at what
information potential research participants wanted to
know.
Of the 20 sections of information NRES suggest
should be included in a PIS, there were seven categories
where no empirical evidence was identified that
2 Kirkby HM, Calvert M, Draper H, et al. BMJ Open (2012). doi:10.1136/bmjopen-2011-000509
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Table 2 Empirical evidence linked to NRES participant information sheet recommended headings
NRES Heading
What does NRES say
should be included?
Number
of studies
Empirical evidence for inclusion
in PIS from literature
What is the
purpose of the
study?
Purpose is an important
consideration for subjects
and should be included
223 32 Pooled results showed that 76%
(95% CI 27% to 100%) participants
wanted to know about study purpose
Why have
I been invited?
Why and how participants
have been chosen and how
many will be in the study
0 No empirical evidence
Do I have to
take part?/What
will happen if
I don’t want to
carry on with
the study?
The voluntary nature of the
research should be included
421e23 32 Pooled results from the 3 quantitative
studies20 29 30 showed that 39%
(95% CI 2% to 100%) participants
wanted to know about voluntariness
The one qualitative study reported that
it was the most important piece of
information to be included in a participant
information sheet31
What will happen
to me if I take
part?/What will
I have to do?
How long the participant will
be involved in the research/
how long the research will last
321 23 32 Pooled results from all three studies20 29 30
showed that 61% (95% CI 16% to 97%)
participants wanted to know how long the
research would last
How often they need to
attend a clinic
121 68% (27/40; 95% CI 53% to 82%)
wanted to know the frequency of
additional study visits29
How long visits will be 0 No empirical evidence
Exactly what will happen
to them
221 22 Specific information types varied
considerably between studies, so no
meaningful pooled results could be calculated
The proportion of people wanting to know
what would happen to them ranged from
9.5% (2/21; 95% CI 0% to 22.1%)31 to 20%
(8/40; 95% CI 7.6% to 32.4%)29 depending
on what the specific information was.
For example, 20% (8/40; 95% CI 7.6% to
32.4%) wanted to know about burdens to
friends or family caused by study participation,29
12% (5/40; 95% CI 2.3% to 22.8%) wanted to
know how much work they would miss
because of study participation,29 10% (4/40;
95% CI 0.7% to 19.3%) wanted to know how
much time would be spent waiting in clinic
during study visits29 and 9.5% (2/21; 95% CI
3% to 22.1%) wanted to know practical
information about trial procedures31
Expenses and
payments
Expense claims available
and if there is any kind of
payment for participation
121 25% (10/40; 95% CI 11.6% to 38.4%) wanted
to know if free medication would be available
during or after trial29
What is the drug,
device or
procedure that
is being tested?
Short description of the
drug, device or procedure
and given the stage of
development state the
dosage of the drug and
method of administration,
and details of any
contraindicated drugs
included over the counter
drugs
221 31 The one quantitative study29 showed that
specific questions about the medication regime
ranged from 25% (10/40; 95% CI 11.5% to
38.4%) that wanted to know what control they
had over medication dose during the study to
70% (28/40; 95% CI 55.8% to 84.2%) that
wanted to know the frequency with which
study medication must be taken.29 The study
also showed that 62% (25/40; 95% CI 47.5% to
77.5%) wanted results of previous studies of
safety and 45% (18/40; 95% CI 29.5% to 60.4%)
of efficacy, and 15% (6/40; 95% CI 3.9% to 26.1%)
wanted to know if study medication had been
approved for clinical use29
The one qualitative study showed that participants
wanted to know how to use the intervention21
Continued
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Table 2 Continued
NRES Heading
What does NRES say
should be included?
Number
of studies
Empirical evidence for inclusion
in PIS from literature
What are the
alternatives for
diagnosis or
treatment?
What other managements/
treatments are available
and a list of all important
comparative risks and
benefit
122 5% (1/21; 95% CI 0% to 13.9%) wanted as much
information about treatment alternatives as they
received about the study medication31
What are the
possible
disadvantages
and risks of taking
part?/What are
the side effects
of any treatment
received when
taking part?
Any risks, discomforts or
inconvenience should be
outlined4
416 23 31 32 Specific information types varied considerably
between studies so no meaningful pooled
results could be calculated. Results ranged
from no participants that asked about study
risks (0/57)20 to 97% (207/213; 95% CI 95%
to 99.4%) who wanted to be informed about
any possible emotional or physical discomforts
and side effects30
Radiation and the
Ionising Radiation
Regulations
If the use of additional
ionising radiation is
required as part of the
study, then information
must be given to the
participant on the radiation
involved
0 No empirical evidence
Harm to the
unborn child:
therapeutic studies
Clear warnings must be
given where there could
be harm to an unborn child,
if there was a risk in breast
feeding or if taking the
medication is likely to
cause fertility problems
0 No empirical evidence
What are the
possible benefits
of taking part?
Benefits should be included,
but where there is no
intended clinical benefit
it should be stated clearly
323 31 32 Pooled results of the two quantitative studies20 30
suggest that 57% (95% CI 7% to 98%) wanted
to know about study benefits
Two studies provided relevant data relating to
specific benefits.29 31 Specific requests ranged
from 14% (3/21; 95% CI 0.7% to 29.3%) that
wanted to know about hopes for better treatment31
to 55% (22/40; 95% CI 39.5% to 70.4%) that
wanted an opportunity to learn about condition or
medication under study.29 Specific information types
varied considerably between studies so no meaningful
pooled results could be calculated
What happens
when the research
study stops?
Arrangements for after
the trial finishes must be
given, and it must be
clear if participants will
have continued access
to any benefits or
intervention they may
have obtained during the
research. If treatment will
not be available after the
study, it should be
explained what treatment
will be available instead
121 55% (22/40; 95% CI 39.6% to 70.4%) wanted to
know about the availability of medication after the
study was over29
What if there
is a problem?
How complaints will be
handled and what redress
may be available
0 No empirical evidence
Will my taking part
in the study be
kept confidential?
How data will be collected,
stored, what it will be used
for, who will have access
to it, how long it will be
retained for and how it will
be disposed of
223 32 Pooled results showed that 44% (95% CI 10%
to 82%) participants wanted to be given
information about confidentiality and the protection
of their privacy
Continued
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Table 2 Continued
NRES Heading
What does NRES say
should be included?
Number
of studies
Empirical evidence for inclusion
in PIS from literature
Involvement of the
GP/family doctor
If the participants GP needs
to be notified of involvement
or asked for consent
0 No empirical evidence
What will happen
to any samples
I give?
Clear description of whether
new samples will be taken,
if excess samples will be
taken, and if access to
existing stored samples will
be required. The same type
of information as for data is
required to be provided
0 No empirical evidence
Will any genetic
tests be done?
A separate consent form for
genetic studies should be used
0 No empirical evidence
What will happen
to the results of the
research study?
What will happen to the results
of the research, if it is intended
to be published and how results
will be made available to
participants and that they will
not be identified in any
publication
328 30 33 Pooled results showed that 91% (95% CI
85% to 95%) wanted to know about study
results
Specific information types varied considerably
between studies, so no meaningful pooled
results could be calculated. Two studies provided
relevant data relating to specific aspects of what
they wanted to know about results.23 28 78%
(31/40; 95% CI 64.6% to 90.4%) of participants
wanted a description of what researchers had learnt
that was important,23 35% (14/40; 95% CI 20.2%
to 49.8%) wanted it to include follow-up contacts for
the researcher23 and 98% (29/40; 95% CI 58.7% to
86.3%) wanted a list of medical publications written
as a results of the research.23 90% (46/51; 95% CI
82% to 98.4%) wanted their family or loved ones to
be informed of the results if they were unable to
learn them28
Continued
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suggested what information research participants wanted
to know (table 2). No further themes, beyond the NRES
categories, were identified. We were able to calculate
pooled proportions for seven themes. Participants
wanted to be told about dissemination of study results
(91% (95% CI 85% to 95%)), investigator conflicts of
interest (48% (95% CI 27% to 69%)), the purpose of the
study (76% (95% CI 27% to 100%)), voluntariness (39%
(95% CI 2% to 100%)), how long the research would last
(61% (95% CI 16% to 97%)), benefits (57% (95% CI 7%
to 98%)) and confidentiality (44% (95% CI 10% to
82%)). Although the majority of participants appeared
to want information for most of these themes, some
participants did not and the level of detail that
participants wanted was not explored comprehensively.
DISCUSSION
Of the 14 papers that met inclusion criteria, five looked
broadly at what information research participants
wanted to know. These studies focused on the category
of information required rather than how much detail
participants wanted. All 14 studies had substantial limi-
tations to generalisability when applied to the wider
research population because, for example, they focused
on specific subsections of the population, for example,
six studies included only cancer patients23 24 26 28 30 31
and only one study conducted in the UK.30 A number of
studies included only women21 26 28 30 and participants
that were mostly Caucasian23 26 and well educated.23e25
In the absence of empirical evidence to suggest what
information potential research participants want, the
NRES have based their guidance on expert opinion. It
does, however, mean that current information provision
for research may not adequately address the informa-
tional needs of the general population or ‘hard to reach’
groups such as socially deprived or AfricaneAmerican
and minority ethnic groups. While the NRES recognise
that one size does not fit all and that low-risk studies with
Table 2 Continued
NRES Heading
What does NRES say
should be included?
Number
of studies
Empirical evidence for inclusion
in PIS from literature
Who is organising
and funding the
research?
The organisation or company
sponsoring the research and
funding the research if these
are different and if the
researcher conducting the
research is being paid
620 24e27 34 Pooled results from the four quantitative studies
showed that 48% (95% CI 27% to 69%) wanted to
know about any type of CoI, but there was general
disagreement over whether patients wanted to be
told about financial CoI
Three studies provided relevant data relating to
what participants wanted to know about specific
aspects of COI.24 27 34 When financial CoI were
broken down into subcategories, 82.5% (4519/
5478; 95% CI 81.48% to 83.5%) wanted to be
told about commercial funding,27 69% (3779/5478;
95% CI 67.8% to 70.2%) about personal
income,27 between 41% (105/259; 95% CI 34.6%
to 46.5%) and 82% (4492/5478; 95% CI 81%
to 83%) about patents and stocks and shares27 34
and 40% (101/253; 95% CI 34% to 46%) thought
researchers should have told participants only
about the oversight system24
One study reported that participants wanted to know
specifically how money was spent, with proportions
ranging from 25% (65/259; 95% CI 19.8% to 30.4%)
that wanted to know how much of the funding was
spent on administration34 to 38% (98/259; 95% CI
31.9% to 43.8%) that wanted to know how spare
accrued funds were used at study completion34
One qualitative study reported that participants
wanted to know the name of the sponsor27 and
one quantitative study reported that 57% (148/259;
95% CI 51.1% to 63.2%)34 wanted to know the
name of the funder
Some participants wanted help understanding the
potential consequences of CoI, some did not25
Specific information types varied considerably
between studies so no meaningful pooled results
could not be calculated
Who has reviewed
the study?
Explain the role of the
research ethics committees
and which committee
reviewed the current study
123 No participants asked about institutional review
board approval (0/57)20
GP, general practitioner; NRES, National Research Ethics Service; PIS, participant information sheet.
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little or no intervention may need shorter information
sheets, there is little empirical evidence to identify what
level of information provision should be made.32 A
potential difficulty in conducting research to determine
what should be included in a PIS is that an individual’s
information preferences may change as they move from
being a potential to actual participant.35 36
Responding to individuals’ information needs may
prove challenging, but the provision of high-quality
appropriate information in a timely manner is crucial to
the consent process. Electronic information provision
may be one way to address different information needs.
Recent research by Antoniou et al37 that allowed partic-
ipants to access three increasingly detailed levels of
information electronically found that the basic level of
information was accessed by 70%e82% of participants,
but only 9%e18% accessed the level of information
currently recommended in NRES guidance and only
3%e12% accessed all three levels of information. Inter-
estingly, 20% (93/552) participants that said they wanted
more information even though fewer than this
(3%e12%) read all the information available to them.
The study by Antoniou et al37 is an important first step
in determining what information potential research
participants really want to know when they agree to take
part in a study. Further research is required to assess the
feasibility and acceptability of unfolding electronic
information sheets.
Limitations
Ideally, differences in informational requirements for
subgroups of the population would have been explored
but the small numbers of studies identified and limited
data extracted from papers meant this was not feasible.
Figure 1 Results of search
strategy and identification of
publications included in the
review.
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Conclusions
There is limited empirical evidence as to what informa-
tion potential participants want to know at the time they
are deciding whether or not to participate in research.
Real-time studies need to be conducted to explore what
information potential participants access when given
a choice. This will enable us to determine exactly what
information research participants want to know and
could, in addition to other sources such as expert
opinion, help tailor PIS towards specific population
subgroups and enable appropriate high-quality infor-
mation to be provided to meet individual needs.
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